Stockreport

Regeneron's Ebola Approval, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha]

AnaptysBio, Inc.  (ANAB) 
Last anaptysbio, inc. earnings: 3/2 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: ir.anaptysbio.com/investor-relations
PDF SummaryRegeneron announces FDA approval for Ebola treatment REGN-EB3.Pluristem receives approval for Cohort II of Chronic Graft vs. Host Disease Study.AnaptysBio announc [Read more]